Global Myasthenia Gravis Market

Global Myasthenia Gravis Market Size Insights Forecasts to 2035

• The Global Myasthenia Gravis Market Size Was valued at USD 1.5 Billion in 2024
• The Global Myasthenia Gravis Market Size is Expected to Grow at a CAGR of around 5.49% from 2025 to 2035
• The Worldwide Myasthenia Gravis Market Size is Expected to Reach USD 5.19 Billion by 2035
• Asia-Pacific is expected to grow the fastest during the forecast period.

According to a research report published by Decisions Advisors and Consulting, The Global Myasthenia Gravis Market Size Was Worth Around USD 1.5 Billion In 2024 And Is Predicted To Grow To Around USD 2.7 Billion By 2035 With A Compound Annual Growth Rate (CAGR) Of 5.49% From 2025 To 2035. The combination of increasing disease awareness and rising targeted biologic therapy adoption together with expanding clinical research efforts and enhanced diagnostic technology and governmental initiatives which enhance patient treatment access.

 

Market Overview

The international myasthenia gravis market represents the medical sector that develops and manufactures and distributes treatments which help in diagnosing and treating Myasthenia Gravis. This disease is an ongoing autoimmune neuromuscular disorder which leads to muscle weakness and fatigue in patients. Additionally, the myasthenia gravis market is currently experiencing substantial growth because of better treatment solutions and heightened public knowledge about the disease. Research into this neuromuscular disorder by healthcare experts and scientists results in new treatment approaches which will help patients achieve better results. The increasing understanding of Myasthenia Gravis together with better diagnostic methods, is creating new possibilities for medical professionals to handle patient treatment and their overall care. This change will create a treatment system which provides customized medical solutions to meet the specific requirements of people who have this condition. The Myasthenia Gravis Market will experience growth because pharmaceutical companies and academic institutions and healthcare providers work together on their research projects. The collaborative work between these organizations will lead to two main outcomes, first developing new medical treatments, second improving patient access to existing medical solutions. The global population will experience a higher incidence of autoimmune disorders including Myasthenia Gravis because of aging, which creates a need for better treatment methods. The market's evolution suggests a promising future, with potential breakthroughs on the horizon that could significantly impact the lives of those living with this condition.

 

Report Coverage

This research report categorizes the myasthenia gravis market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the myasthenia gravis market. Recent market developments and competitive strategies such as expansion, type launch, development, partnership, merger, and acquisition, have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the myasthenia gravis market.

 

Driving Factors

The global myasthenia gravis market Industry experiences rising demand because more people develop myasthenia gravis, which is a chronic autoimmune disorder that leads to muscle weakness. Current estimates show that approximately 20 cases of the disease occur for every 100000 people, while women especially those between 20 and 40 years old show higher rates of the disease. The increasing number of patients who require a cure will create a market opportunity for businesses that develop new therapies and treatment solutions. The global myasthenia gravis market industry needs effective management strategies because the population will continue to grow and people will start developing this condition.

 

Restraining Factors

The myasthenia gravis market throughout the world faces market limitations because expensive treatment options and insufficient medical knowledge in developing areas and difficult diagnosis procedures and immunosuppressive drug side effects and limited availability of advanced biologic therapies.

 

Market Segmentation

The myasthenia gravis market share is classified into treatment type and route of administration.

 

• The immunosuppressants segment dominated the market in 2024, approximately 38% and is projected to grow at a substantial CAGR during the forecast period.

Based on the treatment type, the myasthenia gravis market is divided into anticholinesterase agents, immunosuppressants, intravenous immunoglobulin, plasmapheresis, and thymectomy. Among these, the immunosuppressants segment dominated the market in 2024, approximately 38% and is projected to grow at a substantial CAGR during the forecast period. The drugs help control myasthenia gravis because they can regulate the immune system which causes the disease. The drugs reduce antibody production while they enhance muscle strength and help patients handle their long-term symptoms. The market segment experiences constant growth because more doctors choose to use advanced immunosuppressive treatments which research studies continue to develop.

 

• The oral segment accounted for the largest share in 2024, approximately 52% and is anticipated to grow at a significant CAGR during the forecast period.

Based on the route of administration, the myasthenia gravis market is divided into oral, intravenous, and subcutaneous. Among these, the oral segment accounted for the largest share in 2024, approximately 52% and is anticipated to grow at a significant CAGR during the forecast period. The treatment of myasthenia gravis through oral medications which people prefer and which doctors find easy to use has become the standard method because of these benefits. Doctors first prescribe oral medications which include anticholinesterase agents and immunosuppressants as their initial treatment for patients. The market expansion of the segment results from three factors which include its broad product distribution and its more affordable treatment options than injectable treatments and its better patient compliance with the treatment.

Regional Segment Analysis of the Myasthenia Gravis Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

 

North America is anticipated to hold the largest share of the myasthenia gravis market over the predicted timeframe.

North America is anticipated to hold the largest share of the myasthenia gravis market over the predicted timeframe. The region's growth is driven by increasing prevalence rates, advancements in treatment options, and supportive regulatory frameworks. The FDA's expedited approval processes for innovative therapies further catalyze market expansion, meeting the rising demand for effective treatments. The competitive landscape in North America is robust, featuring key players such as Roche, Bristol-Myers Squibb, and Pfizer. These companies are actively engaged in research and development, focusing on novel therapies and personalized medicine. The established healthcare infrastructure combined with clinical trial investments creates a market environment which leads to Myasthenia Gravis industry expansion and innovative developments.

 

Asia-Pacific is expected to grow at a rapid CAGR in the myasthenia gravis market during the forecast period. The demand for medical services is rising because healthcare investments are increasing and people now understand more about neurological disorders and there are more patients requiring treatment. The market in this area will experience growth because government programs work to increase healthcare services for people who need them. Japan China and Australia are emerging as leading countries which conduct more clinical trials and research studies. Eisai and Amgen lead the pharmaceutical industry by creating new treatments which specifically address regional healthcare requirements. The market system is changing because local companies and international businesses are starting to work together to improve treatment access for patients and their health results.

 

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the myasthenia gravis market, along with a comparative evaluation primarily based on their type of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes type development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

 

List of Key Companies

• argenx SE
• UCB S.A.
• Johnson & Johnson
• Novartis AG
• AstraZeneca plc
• Mitsubishi Tanabe Pharma
• CSL Behring
• Horizon Therapeutics
• Immunovant Inc.
• Alexion Pharmaceuticals
• Others

 

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

 

Recent Development

 

• In December 2025, the U.S. Food and Drug Administration had approved Uplizna (inebilizumab-cdon) from Amgen for adults with generalized myasthenia gravis who were anti-AChR or anti-MuSK antibody positive. The CD19-targeted B-cell therapy had offered long-term disease control with only two maintenance doses per year after initial loading doses.

 

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Decisions Advisors has segmented the myasthenia gravis market based on the below-mentioned segments: 

 

Global Myasthenia Gravis Market, By Treatment Type

• Anticholinesterase Agents
• Immunosuppressants
• Intravenous Immunoglobulin
• Plasmapheresis
• Thymectomy

 

Global Myasthenia Gravis Market, By Route of Administration

• Oral
• Intravenous
• Subcutaneous

 

Global Myasthenia Gravis Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  •  South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa

 

Frequently Asked Questions (FAQ)

 

1. What is driving the growth of the Global Myasthenia Gravis Market?

A: The market growth is driven by rising disease prevalence, increasing awareness, advancements in targeted biologic therapies, improved diagnostic technologies, expanding clinical research, and supportive government initiatives improving treatment accessibility.

 

2. Which treatment type dominated the Myasthenia Gravis Market in 2024?

A: Immunosuppressants dominated the market in 2024 with about 38% share, as they regulate the immune system, reduce antibody production, improve muscle strength, and effectively manage long-term symptoms.

 

3. Why does the oral route of administration lead the Myasthenia Gravis Market?

A: The oral segment leads the market due to convenience, affordability, and better patient compliance. Doctors commonly prescribe oral anticholinesterase agents and immunosuppressants as first-line therapies for managing myasthenia gravis symptoms.

 

4. Which region holds the largest share in the Global Myasthenia Gravis Market?

A: North America holds the largest market share due to advanced healthcare infrastructure, high disease awareness, strong regulatory support, rapid drug approvals, and active research and development by leading pharmaceutical companies.

 

5. Why is Asia-Pacific expected to grow fastest in the Myasthenia Gravis Market?

A: Asia-Pacific is expected to grow fastest because of increasing healthcare investments, rising neurological disorder awareness, growing patient population, government healthcare initiatives, and expanding clinical trials in countries like China, Japan, and India.